• Breast Cancer Disease Site Group, Systemic Treatment Disease Site Group. Findlay BP, Walker-Dilks C, Pritchard K. Epirubicin, as a single agent or in combination, for metastatic breast cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Apr 30 [online update]. 15 p. (Practice guideline report; no. 1-6). [21 references]

Epirubicin, at doses equivalent to doxorubicin, has been shown to be equally efficacious and less toxic than doxorubicin. Doxorubicin, however, is an acceptable alternative.

None provided

The recommendations are supported by randomized controlled trials.

• Breast Cancer Disease Site Group, Systemic Treatment Disease Site Group. Findlay BP, Walker-Dilks C, Pritchard K. Epirubicin, as a single agent or in combination, for metastatic breast cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Apr 30 [online update]. 15 p. (Practice guideline report; no. 1-6). [21 references]

Not applicable: The guideline was not adapted from another source.

1997 Mar 11 (updated online 2003 Apr 30)

Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]

The Practice Guidelines Initiative (PGI) is the main project of the Program in Evidence-based Care (PEBC), a Province of Ontario initiative sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.

Cancer Care Ontario, Ontario Ministry of Health and Long-Term Care

Breast Cancer Disease Site Group
Systemic Treatment Disease Site Group

Members of the Breast Cancer Disease Site Group disclosed potential conflict of interest information.

None available

This summary was completed by ECRI on January 5, 1999. The information was verified by the guideline developer as of February 22, 1999. This NGC summary was updated by ECRI on December 3, 2001. The updated information was reviewed by the guideline developer as of January 10, 2002. This summary was updated again by ECRI on July 5, 2002. The updated information was verified by the guideline developer on August 19, 2002. This summary was most recently updated by ECRI on April 19, 2004. The updated information was verified by the guideline developer on April 29, 2004.